Search

Your search keyword '"Kochupurakkal, Bose"' showing total 225 results
Start Over Author "Kochupurakkal, Bose"
225 results on '"Kochupurakkal, Bose"'

1. A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE).

Author

Pan, Elizabeth, Xie, Wanling, Ajmera, Archana, Araneta, Arlene, Jamieson, Christina, Folefac, Edmund, Hussain, Arif, Kyriakopoulos, Christos, Olson, Adam, Parikh, Rahul, Saraiya, Biren, Ivy, S, Van Allen, Eliezer, Lindeman, Neal, Kochupurakkal, Bose, Shapiro, Geoffrey, McKay, Rana, and Parikh, Mamta

Subjects
Male, Humans, Prostatic Neoplasms, Castration-Resistant, Antineoplastic Agents, Fatigue
Abstract

Given that radium-223 is a radiopharmaceutical that induces DNA damage, and olaparib is a PARP inhibitor that interferes with DNA repair mechanisms, we hypothesized their synergy in metastatic castration-resistant prostate cancer (mCRPC). We sought to demonstrate the safety and efficacy of olaparib + radium-223. We conducted a multicenter phase I 3+3 dose escalation study of olaparib with fixed dose radium-223 in patients with mCRPC with bone metastases. The primary objective was to establish the RP2D of olaparib, with secondary objectives of safety, PSA response, alkaline phosphatase response, radiographic progression-free survival (rPFS), overall survival, and efficacy by homologous recombination repair (HRR) gene status. Twelve patients were enrolled; all patients received a prior androgen receptor signaling inhibitor (ARSI; 100%) and 3 patients (25%) prior docetaxel. Dose-limiting toxicities (DLT) included cytopenias, fatigue, and nausea. No DLTs were seen in the observation period however delayed toxicities guided the RP2D. The RP2D of olaparib was 200 mg orally twice daily with radium-223. The most common treatment-related adverse events were fatigue (92%) and anemia (58%). The rPFS at 6 months was 58% (95% confidence interval, 27%-80%). Nine patients were evaluable for HRR gene status; 1 had a BRCA2 alteration (rPFS 11.8 months) and 1 had a CDK12 alteration (rPFS 3.1 months). Olaparib can be safely combined with radium-223 at the RP2D 200 mg orally twice daily with fixed dose radium-223. Early clinical benefit was observed and will be investigated in a phase II study.

Published
2023

2. A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors.

Author

Zhou, Jia, Gelot, Camille, Pantelidou, Constantia, Li, Adam, Yücel, Hatice, Davis, Rachel, Färkkilä, Anniina, Kochupurakkal, Bose, Syed, Aleem, Shapiro, Geoffrey, Tainer, John, Blagg, Brian, Ceccaldi, Raphael, and DAndrea, Alan

Subjects
Fanconi Anemia, HRD cancer, Homologous Recombination, MMEJ, Novobiocin, PARP inhibitor resistance, Polymerase theta (POLθ), Adenosine Triphosphatases, Female, Homologous Recombination, Humans, Ovarian Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors
Abstract

DNA polymerase theta (POLθ) is synthetic lethal with Homologous Recombination (HR) deficiency and thus a candidate target for HR-deficient cancers. Through high-throughput small molecule screens we identified the antibiotic Novobiocin (NVB) as a specific POLθ inhibitor that selectively kills HR-deficient tumor cells in vitro and in vivo. NVB directly binds to the POLθ ATPase domain, inhibits its ATPase activity, and phenocopies POLθ depletion. NVB kills HR-deficient breast and ovarian tumors in GEMM, xenograft and PDX models. Increased POLθ levels predict NVB sensitivity, and BRCA-deficient tumor cells with acquired resistance to PARP inhibitors (PARPi) are sensitive to NVB in vitro and in vivo. Mechanistically, NVB-mediated cell death in PARPi-resistant cells arises from increased double-strand break end resection, leading to accumulation of single-strand DNA intermediates and non-functional RAD51 foci. Our results demonstrate that NVB may be useful alone or in combination with PARPi in treating HR-deficient tumors, including those with acquired PARPi resistance. (151/150).

Published
2021

3. Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses

Author

Konstantinopoulos, Panagiotis A., Cheng, Su-Chun, Lee, Elizabeth K., da Costa, Alexandre André B.A., Gulhan, Doga, Wahner Hendrickson, Andrea E., Kochupurakkal, Bose, Kolin, David L., Kohn, Elise C., Liu, Joyce F., Penson, Richard T., Stover, Elizabeth H., Curtis, Jennifer, Sawyer, Hannah, Polak, Madeline, Chowdhury, Dipanjan, DʼAndrea, Alan D., Färkkilä, Anniina, Shapiro, Geoffrey I., and Matulonis, Ursula A.

Published
2024
Full Text
View/download PDF

4. PARG inhibitor sensitivity correlates with accumulation of single- stranded DNA gaps in preclinical models of ovarian cancer.

Author

Ravindranathan, Ramya, Somuncu, Ozge, da Costa, Alexandre André B. A., Mukkavalli, Sirisha, Lamarre, Benjamin P., Huy Nguyen, Grochala, Carter, Yuqing Jiao, Joyce Liu, Kochupurakkal, Bose, Parmar, Kalindi, Shapiro, Geoffrey I., and D'Andrea, Alan D.

Subjects
SINGLE-stranded DNA, HOMOLOGOUS recombination, OVARIAN cancer, CANCER cells, DNA repair
Abstract

Poly (ADP-ribose) glycohydrolase (PARG) is a dePARylating enzyme which promotes DNA repair by removal of poly (ADP-ribose) (PAR) from PARylated proteins. Loss or inhibition of PARG results in replication stress and sensitizes cancer cells to DNA-damaging agents. PARG inhibitors are now undergoing clinical development for patients having tumors with homologous recombination deficiency (HRD), such as cancer patients with germline or somatic BRCA1/2-mutations. PARP inhibitors kill BRCA-deficient cancer cells by increasing single-stranded DNA gaps (ssGAPs) during replication. Here, we report that, like PARP inhibitor (PARPi), PARG inhibitor (PARGi) treatment also causes an accumulation of ssGAPs in sensitive cells. PARGi exposure increased accumulation of S-phase-specific PAR, a marker for Okazaki fragment processing (OFP) defects on lagging strands and induced ssGAPs, in sensitive cells but not in resistant cells. PARGi also caused accumulation of PAR at the replication forks and at the ssDNA sites in sensitive cells. Additionally, PARGi exhibited monotherapy activity in specific HR-deficient, as well as HR-proficient, patient-derived, or patient-derived xenograft (PDX)-derived organoids of ovarian cancer, and drug sensitivity directly correlated with the accumulation of ssGAPs. Taken together, PARGi treatment results in toxic accumulation of PAR at replication forks resulting in ssGAPs due to OFP defects during replication. Regardless of the BRCA/HRD-status, the induction of ssGAPs in preclinical models of ovarian cancer cells correlates with PARGi sensitivity. Patient-derived organoids (PDOs) may be a useful model system for testing PARGi sensitivity and functional biomarkers. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia

Author

Pouliot, Gayle P, Degar, James, Hinze, Laura, Kochupurakkal, Bose, Vo, Chau D, Burns, Melissa A, Moreau, Lisa, Ganesa, Chirag, Roderick, Justine, Peirs, Sofie, Menten, Bjorn, Loh, Mignon L, Hunger, Stephen P, Silverman, Lewis B, Harris, Marian H, Stevenson, Kristen E, Weinstock, David M, Weng, Andrew P, Van Vlierberghe, Pieter, D’Andrea, Alan D, and Gutierrez, Alejandro

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Genetics, Oncology and Carcinogenesis, Hematology, Pediatric Cancer, Orphan Drug, Pediatric, Childhood Leukemia, Pediatric Research Initiative, Cancer, Rare Diseases, Human Genome, Aetiology, 2.1 Biological and endogenous factors, Animals, BRCA2 Protein, Cell Line, Tumor, Child, Fanconi Anemia Complementation Group D2 Protein, Genes, BRCA1, Genes, BRCA2, Haploinsufficiency, Heterografts, Humans, Jurkat Cells, Male, Mice, Mice, Inbred NOD, Mutagenesis, Site-Directed, Mutation, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Radiation Tolerance, Sequence Analysis, DNA, Sequence Analysis, RNA, Ultraviolet Rays, General Science & Technology
Abstract

BRCA2 (also known as FANCD1) is a core component of the Fanconi pathway and suppresses transformation of immature T-cells in mice. However, the contribution of Fanconi-BRCA pathway deficiency to human T-cell acute lymphoblastic leukemia (T-ALL) remains undefined. We identified point mutations in 9 (23%) of 40 human T-ALL cases analyzed, with variant allele fractions consistent with heterozygous mutations early in tumor evolution. Two of these mutations were present in remission bone marrow specimens, suggesting germline alterations. BRCA2 was the most commonly mutated gene. The identified Fanconi-BRCA mutations encode hypomorphic or null alleles, as evidenced by their inability to fully rescue Fanconi-deficient cells from chromosome breakage, cytotoxicity and/or G2/M arrest upon treatment with DNA cross-linking agents. Disabling the tumor suppressor activity of the Fanconi-BRCA pathway is generally thought to require biallelic gene mutations. However, all mutations identified were monoallelic, and most cases appeared to retain expression of the wild-type allele. Using isogenic T-ALL cells, we found that BRCA2 haploinsufficiency induces selective hypersensitivity to ATR inhibition, in vitro and in vivo. These findings implicate Fanconi-BRCA pathway haploinsufficiency in the molecular pathogenesis of T-ALL, and provide a therapeutic rationale for inhibition of ATR or other druggable effectors of homologous recombination.

Published
2019

7. A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer

Author

Konstantinopoulos, Panagiotis A., da Costa, Alexandre André B. A., Gulhan, Doga, Lee, Elizabeth K., Cheng, Su-Chun, Hendrickson, Andrea E. Wahner, Kochupurakkal, Bose, Kolin, David L., Kohn, Elise C., Liu, Joyce F., Stover, Elizabeth H., Curtis, Jennifer, Tayob, Nabihah, Polak, Madeline, Chowdhury, Dipanjan, Matulonis, Ursula A., Färkkilä, Anniina, D’Andrea, Alan D., and Shapiro, Geoffrey I.

Published
2021
Full Text
View/download PDF

9. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial

Author

Konstantinopoulos, Panagiotis A, Barry, William T, Birrer, Michael, Westin, Shannon N, Cadoo, Karen A, Shapiro, Geoffrey I, Mayer, Erica L, O'Cearbhaill, Roisin E, Coleman, Robert L, Kochupurakkal, Bose, Whalen, Christin, Curtis, Jennifer, Farooq, Sarah, Luo, Weixiu, Eismann, Julia, Buss, Mary K, Aghajanian, Carol, Mills, Gordon B, Palakurthi, Sangeetha, Kirschmeier, Paul, Liu, Joyce, Cantley, Lewis C, Kaufmann, Scott H, Swisher, Elizabeth M, D'Andrea, Alan D, Winer, Eric, Wulf, Gerburg M, and Matulonis, Ursula A

Published
2019
Full Text
View/download PDF

10. Abstract B005: A phase 1 expansion cohort study evaluating the safety and efficacy of the CHK1 inhibitor LY2880070 with low-dose gemcitabine in metastatic pancreatic adenocarcinoma

Author

Huffman, Brandon M., primary, Feng, Hanrong, additional, Parmar, Kalindi, additional, Wang, Junning, additional, Kapner, Kevin, additional, Kochupurakkal, Bose, additional, Martignetti, David, additional, Abrams, Thomas, additional, Biller, Leah, additional, Giannakis, Marios, additional, Ng, Kimmie, additional, Patel, Anuj, additional, Perez, Kimberly, additional, Singh, Harshabad, additional, Rubinson, Douglas, additional, Schlechter, Benjamin, additional, Andrews, Elizabeth, additional, Hannigan, Alison, additional, Dunwell, Stanley, additional, Getchell, Zoe, additional, Raghavan, Srivatsan, additional, Wolpin, Brian, additional, D'Andrea, Alan, additional, Aguirre, Andrew, additional, Shapiro, Geoffrey, additional, and Cleary, James, additional

Published
2024
Full Text
View/download PDF

11. Supplementary Figures S1-S2 from A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma

Author

Huffman, Brandon M., primary, Feng, Hanrong, primary, Parmar, Kalindi, primary, Wang, Junning, primary, Kapner, Kevin S., primary, Kochupurakkal, Bose, primary, Martignetti, David B., primary, Sadatrezaei, Golbahar, primary, Abrams, Thomas A., primary, Biller, Leah H., primary, Giannakis, Marios, primary, Ng, Kimmie, primary, Patel, Anuj K., primary, Perez, Kimberly J., primary, Singh, Harshabad, primary, Rubinson, Douglas A., primary, Schlechter, Benjamin L., primary, Andrews, Elizabeth, primary, Hannigan, Alison M., primary, Dunwell, Stanley, primary, Getchell, Zoe, primary, Raghavan, Srivatsan, primary, Wolpin, Brian M., primary, Fortier, Caroline, primary, D'Andrea, Alan D., primary, Aguirre, Andrew J., primary, Shapiro, Geoffrey I., primary, and Cleary, James M., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Table S1 from A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma

Author

Huffman, Brandon M., primary, Feng, Hanrong, primary, Parmar, Kalindi, primary, Wang, Junning, primary, Kapner, Kevin S., primary, Kochupurakkal, Bose, primary, Martignetti, David B., primary, Sadatrezaei, Golbahar, primary, Abrams, Thomas A., primary, Biller, Leah H., primary, Giannakis, Marios, primary, Ng, Kimmie, primary, Patel, Anuj K., primary, Perez, Kimberly J., primary, Singh, Harshabad, primary, Rubinson, Douglas A., primary, Schlechter, Benjamin L., primary, Andrews, Elizabeth, primary, Hannigan, Alison M., primary, Dunwell, Stanley, primary, Getchell, Zoe, primary, Raghavan, Srivatsan, primary, Wolpin, Brian M., primary, Fortier, Caroline, primary, D'Andrea, Alan D., primary, Aguirre, Andrew J., primary, Shapiro, Geoffrey I., primary, and Cleary, James M., primary

Published
2023
Full Text
View/download PDF

13. A Phase 1 Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-Dose Gemcitabine in Metastatic Pancreatic Adenocarcinoma Patients

Author

Huffman, Brandon M., primary, Feng, Hanrong, additional, Parmar, Kalindi, additional, Wang, Junning, additional, Kapner, Kevin S., additional, Kochupurakkal, Bose, additional, Martignetti, David B., additional, Sadatrezaei, Golbahar, additional, Abrams, Thomas A., additional, Biller, Leah H., additional, Giannakis, Marios, additional, Ng, Kimmie, additional, Patel, Anuj K., additional, Perez, Kimberly J., additional, Singh, Harshabad, additional, Rubinson, Douglas A., additional, Schlechter, Benjamin L., additional, Andrews, Elizabeth, additional, Hannigan, Alison M., additional, Dunwell, Stanley, additional, Getchell, Zoe, additional, Raghavan, Srivatsan, additional, Wolpin, Brian M., additional, Fortier, Caroline, additional, D'Andrea, Alan D., additional, Aguirre, Andrew J., additional, Shapiro, Geoffrey I., additional, and Cleary, James M., additional

Published
2023
Full Text
View/download PDF

14. Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer

Author

Färkkilä, Anniina, Gulhan, Doga C., Casado, Julia, Jacobson, Connor A., Nguyen, Huy, Kochupurakkal, Bose, Maliga, Zoltan, Yapp, Clarence, Chen, Yu-An, Schapiro, Denis, Zhou, Yinghui, Graham, Julie R., Dezube, Bruce J., Munster, Pamela, Santagata, Sandro, Garcia, Elizabeth, Rodig, Scott, Lako, Ana, Chowdhury, Dipanjan, Shapiro, Geoffrey I., Matulonis, Ursula A., Park, Peter J., Hautaniemi, Sampsa, Sorger, Peter K., Swisher, Elizabeth M., D’Andrea, Alan D., and Konstantinopoulos, Panagiotis A.

Published
2020
Full Text
View/download PDF

15. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer

Author

Färkkilä, Anniina, Gulhan, Doga C., Casado, Julia, Jacobson, Connor A., Nguyen, Huy, Kochupurakkal, Bose, Maliga, Zoltan, Yapp, Clarence, Chen, Yu-An, Schapiro, Denis, Zhou, Yinghui, Graham, Julie R., Dezube, Bruce J., Munster, Pamela, Santagata, Sandro, Garcia, Elizabeth, Rodig, Scott, Lako, Ana, Chowdhury, Dipanjan, Shapiro, Geoffrey I., Matulonis, Ursula A., Park, Peter J., Hautaniemi, Sampsa, Sorger, Peter K., Swisher, Elizabeth M., D’Andrea, Alan D., and Konstantinopoulos, Panagiotis A.

Published
2020
Full Text
View/download PDF

16. Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)

Author

Ingham, Matthew, primary, Allred, Jacob B., additional, Chen, Li, additional, Das, Biswasjit, additional, Kochupurakkal, Bose, additional, Gano, Katherine, additional, George, Suzanne, additional, Attia, Steven, additional, Burgess, Melissa A., additional, Seetharam, Mahesh, additional, Boikos, Sosipatros A., additional, Bui, Nam, additional, Chen, James L., additional, Close, Julia L., additional, Cote, Gregory M., additional, Thaker, Premal H., additional, Ivy, S. Percy, additional, Bose, Sminu, additional, D'Andrea, Alan, additional, Marino-Enriquez, Adrian, additional, Shapiro, Geoffrey I., additional, and Schwartz, Gary K., additional

Published
2023
Full Text
View/download PDF

17. Abstract CT188: A phase Ib study of sapacitabine (sapa) and olaparib (ola) in patients (pts) with BRCA1/2-mutated (BRCA1/2m) metastatic breast cancer (MBC)

Author

Lynce, Filipa, primary, Graham, Noah, additional, Kochupurakkal, Bose S., additional, Nguyen, Huy, additional, Poorvu, Philip D., additional, Attaya, Victoria, additional, Davis, Raechel, additional, Garg, Kavita, additional, Lim, Lee P., additional, Li, Mark, additional, Paweletz, Cloud P., additional, Tayob, Nabihah, additional, Shapiro, Geoffrey I., additional, and Tolaney, Sara M., additional

Published
2023
Full Text
View/download PDF

18. Abstract 6210: Combination of M1774 and niraparib can overcome ATR and PARP inhibitor resistance in BRCA1 mutated ovarian cancer models

Author

Hao, Jie, primary, Bose, Arindam, additional, Sadatrezaei, Golbahar, additional, Martignetti, David B., additional, Jiao, Yuqing, additional, da Costa, Alexandre André B., additional, Lazaro, Jean-Bernard, additional, Kochupurakkal, Bose, additional, Nguyen, Huy, additional, Parmar, Kalindi, additional, D’Andrea, Alan D., additional, and Shapiro, Geoffrey I., additional

Published
2023
Full Text
View/download PDF

19. Supplementary Data from A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE)

Author

Pan, Elizabeth, primary, Xie, Wanling, primary, Ajmera, Archana, primary, Araneta, Arlene, primary, Jamieson, Christina, primary, Folefac, Edmund, primary, Hussain, Arif, primary, Kyriakopoulos, Christos E., primary, Olson, Adam, primary, Parikh, Mamta, primary, Parikh, Rahul, primary, Saraiya, Biren, primary, Ivy, S. Percy, primary, Van Allen, Eliezer M., primary, Lindeman, Neal I., primary, Kochupurakkal, Bose S., primary, Shapiro, Geoffrey I., primary, and McKay, Rana R., primary

Published
2023
Full Text
View/download PDF

20. Abstract 5725: The USP1 inhibitor I-138 kills BRCA1-deficient tumor cells and overcomes PARP inhibitor resistance

Author

Da Costa, Alexandre Andre B. A., primary, Bose, Arindam, additional, Martignetti, David, additional, Ayala-Zambrano, Cecilia, additional, Ravindranathan, Ramya, additional, Sadatrezaei, Golbahar, additional, Jiao, Yuqing, additional, Kochupurakkal, Bose, additional, Nguyen, Huy, additional, Lazaro, Jean-Bernard, additional, Parmar, Kalindi, additional, Shapiro, Geoffrey I., additional, and D’Andrea, Alan D., additional

Published
2023
Full Text
View/download PDF

21. Data from A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE)

Author

Pan, Elizabeth, primary, Xie, Wanling, primary, Ajmera, Archana, primary, Araneta, Arlene, primary, Jamieson, Christina, primary, Folefac, Edmund, primary, Hussain, Arif, primary, Kyriakopoulos, Christos E., primary, Olson, Adam, primary, Parikh, Mamta, primary, Parikh, Rahul, primary, Saraiya, Biren, primary, Ivy, S. Percy, primary, Van Allen, Eliezer M., primary, Lindeman, Neal I., primary, Kochupurakkal, Bose S., primary, Shapiro, Geoffrey I., primary, and McKay, Rana R., primary

Published
2023
Full Text
View/download PDF

22. Supplementary Table 5 from Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids

Author

Hill, Sarah J., primary, Decker, Brennan, primary, Roberts, Emma A., primary, Horowitz, Neil S., primary, Muto, Michael G., primary, Worley, Michael J., primary, Feltmate, Colleen M., primary, Nucci, Marisa R., primary, Swisher, Elizabeth M., primary, Nguyen, Huy, primary, Yang, Chunyu, primary, Morizane, Ryuji, primary, Kochupurakkal, Bose S., primary, Do, Khanh T., primary, Konstantinopoulos, Panagiotis A., primary, Liu, Joyce F., primary, Bonventre, Joseph V., primary, Matulonis, Ursula A., primary, Shapiro, Geoffrey I., primary, Berkowitz, Ross S., primary, Crum, Christopher P., primary, and D'Andrea, Alan D., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Figures 1 - 6 from NF-κB Activation-Induced Anti-apoptosis Renders HER2-Positive Cells Drug Resistant and Accelerates Tumor Growth

Author

Bailey, Shannon T., primary, Miron, Penelope L., primary, Choi, Yoon J., primary, Kochupurakkal, Bose, primary, Maulik, Gautam, primary, Rodig, Scott. J., primary, Tian, Ruiyang, primary, Foley, Kathleen M., primary, Bowman, Teresa, primary, Miron, Alexander, primary, Brown, Myles, primary, Iglehart, J. Dirk., primary, and Biswas, Debajit K., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Table 1 from Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids

Author

Hill, Sarah J., primary, Decker, Brennan, primary, Roberts, Emma A., primary, Horowitz, Neil S., primary, Muto, Michael G., primary, Worley, Michael J., primary, Feltmate, Colleen M., primary, Nucci, Marisa R., primary, Swisher, Elizabeth M., primary, Nguyen, Huy, primary, Yang, Chunyu, primary, Morizane, Ryuji, primary, Kochupurakkal, Bose S., primary, Do, Khanh T., primary, Konstantinopoulos, Panagiotis A., primary, Liu, Joyce F., primary, Bonventre, Joseph V., primary, Matulonis, Ursula A., primary, Shapiro, Geoffrey I., primary, Berkowitz, Ross S., primary, Crum, Christopher P., primary, and D'Andrea, Alan D., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Table 2 from Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids

Author

Hill, Sarah J., primary, Decker, Brennan, primary, Roberts, Emma A., primary, Horowitz, Neil S., primary, Muto, Michael G., primary, Worley, Michael J., primary, Feltmate, Colleen M., primary, Nucci, Marisa R., primary, Swisher, Elizabeth M., primary, Nguyen, Huy, primary, Yang, Chunyu, primary, Morizane, Ryuji, primary, Kochupurakkal, Bose S., primary, Do, Khanh T., primary, Konstantinopoulos, Panagiotis A., primary, Liu, Joyce F., primary, Bonventre, Joseph V., primary, Matulonis, Ursula A., primary, Shapiro, Geoffrey I., primary, Berkowitz, Ross S., primary, Crum, Christopher P., primary, and D'Andrea, Alan D., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Table 3 from Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids

Author

Hill, Sarah J., primary, Decker, Brennan, primary, Roberts, Emma A., primary, Horowitz, Neil S., primary, Muto, Michael G., primary, Worley, Michael J., primary, Feltmate, Colleen M., primary, Nucci, Marisa R., primary, Swisher, Elizabeth M., primary, Nguyen, Huy, primary, Yang, Chunyu, primary, Morizane, Ryuji, primary, Kochupurakkal, Bose S., primary, Do, Khanh T., primary, Konstantinopoulos, Panagiotis A., primary, Liu, Joyce F., primary, Bonventre, Joseph V., primary, Matulonis, Ursula A., primary, Shapiro, Geoffrey I., primary, Berkowitz, Ross S., primary, Crum, Christopher P., primary, and D'Andrea, Alan D., primary

Published
2023
Full Text
View/download PDF

27. Data from Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids

Author

Hill, Sarah J., primary, Decker, Brennan, primary, Roberts, Emma A., primary, Horowitz, Neil S., primary, Muto, Michael G., primary, Worley, Michael J., primary, Feltmate, Colleen M., primary, Nucci, Marisa R., primary, Swisher, Elizabeth M., primary, Nguyen, Huy, primary, Yang, Chunyu, primary, Morizane, Ryuji, primary, Kochupurakkal, Bose S., primary, Do, Khanh T., primary, Konstantinopoulos, Panagiotis A., primary, Liu, Joyce F., primary, Bonventre, Joseph V., primary, Matulonis, Ursula A., primary, Shapiro, Geoffrey I., primary, Berkowitz, Ross S., primary, Crum, Christopher P., primary, and D'Andrea, Alan D., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figure Legend from NF-κB Activation-Induced Anti-apoptosis Renders HER2-Positive Cells Drug Resistant and Accelerates Tumor Growth

Author

Bailey, Shannon T., primary, Miron, Penelope L., primary, Choi, Yoon J., primary, Kochupurakkal, Bose, primary, Maulik, Gautam, primary, Rodig, Scott. J., primary, Tian, Ruiyang, primary, Foley, Kathleen M., primary, Bowman, Teresa, primary, Miron, Alexander, primary, Brown, Myles, primary, Iglehart, J. Dirk., primary, and Biswas, Debajit K., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Text and Figures from Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids

Author

Hill, Sarah J., primary, Decker, Brennan, primary, Roberts, Emma A., primary, Horowitz, Neil S., primary, Muto, Michael G., primary, Worley, Michael J., primary, Feltmate, Colleen M., primary, Nucci, Marisa R., primary, Swisher, Elizabeth M., primary, Nguyen, Huy, primary, Yang, Chunyu, primary, Morizane, Ryuji, primary, Kochupurakkal, Bose S., primary, Do, Khanh T., primary, Konstantinopoulos, Panagiotis A., primary, Liu, Joyce F., primary, Bonventre, Joseph V., primary, Matulonis, Ursula A., primary, Shapiro, Geoffrey I., primary, Berkowitz, Ross S., primary, Crum, Christopher P., primary, and D'Andrea, Alan D., primary

Published
2023
Full Text
View/download PDF

30. Data from NF-κB Activation-Induced Anti-apoptosis Renders HER2-Positive Cells Drug Resistant and Accelerates Tumor Growth

Author

Bailey, Shannon T., primary, Miron, Penelope L., primary, Choi, Yoon J., primary, Kochupurakkal, Bose, primary, Maulik, Gautam, primary, Rodig, Scott. J., primary, Tian, Ruiyang, primary, Foley, Kathleen M., primary, Bowman, Teresa, primary, Miron, Alexander, primary, Brown, Myles, primary, Iglehart, J. Dirk., primary, and Biswas, Debajit K., primary

Published
2023
Full Text
View/download PDF

31. Supplementary Table 4 from Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids

Author

Hill, Sarah J., primary, Decker, Brennan, primary, Roberts, Emma A., primary, Horowitz, Neil S., primary, Muto, Michael G., primary, Worley, Michael J., primary, Feltmate, Colleen M., primary, Nucci, Marisa R., primary, Swisher, Elizabeth M., primary, Nguyen, Huy, primary, Yang, Chunyu, primary, Morizane, Ryuji, primary, Kochupurakkal, Bose S., primary, Do, Khanh T., primary, Konstantinopoulos, Panagiotis A., primary, Liu, Joyce F., primary, Bonventre, Joseph V., primary, Matulonis, Ursula A., primary, Shapiro, Geoffrey I., primary, Berkowitz, Ross S., primary, Crum, Christopher P., primary, and D'Andrea, Alan D., primary

Published
2023
Full Text
View/download PDF

32. Figure S3 from The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition

Author

Parmar, Kalindi, primary, Kochupurakkal, Bose S., primary, Lazaro, Jean-Bernard, primary, Wang, Zhigang C., primary, Palakurthi, Sangeetha, primary, Kirschmeier, Paul T., primary, Yang, Chunyu, primary, Sambel, Larissa A., primary, Färkkilä, Anniina, primary, Reznichenko, Elizaveta, primary, Reavis, Hunter D., primary, Dunn, Connor E., primary, Zou, Lee, primary, Do, Khanh T., primary, Konstantinopoulos, Panagiotis A., primary, Matulonis, Ursula A., primary, Liu, Joyce F., primary, D'Andrea, Alan D., primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

33. Figure S4 from Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors

Author

Do, Khanh T., primary, Kochupurakkal, Bose, primary, Kelland, Sarah, primary, de Jonge, Adrienne, primary, Hedglin, Jennifer, primary, Powers, Allison, primary, Quinn, Nicholas, primary, Gannon, Courtney, primary, Vuong, Loan, primary, Parmar, Kalindi, primary, Lazaro, Jean-Bernard, primary, D'Andrea, Alan D., primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

34. Supplementary Data from Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer

Author

Keenan, Tanya E., primary, Li, Tianyu, primary, Vallius, Tuulia, primary, Guerriero, Jennifer L., primary, Tayob, Nabihah, primary, Kochupurakkal, Bose, primary, Davis, Janae, primary, Pastorello, Ricardo, primary, Tahara, Rie K., primary, Anderson, Leilani, primary, Conway, Jake, primary, He, Meng X., primary, Shannon, Erin, primary, Godin, Robert E., primary, Sorger, Peter K., primary, D'Andrea, Alan, primary, Overmoyer, Beth, primary, Winer, Eric P., primary, Mittendorf, Elizabeth A., primary, Van Allen, Eliezer M., primary, Shapiro, Geoffrey I., primary, and Tolaney, Sara M., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Table S1 from The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition

Author

Parmar, Kalindi, primary, Kochupurakkal, Bose S., primary, Lazaro, Jean-Bernard, primary, Wang, Zhigang C., primary, Palakurthi, Sangeetha, primary, Kirschmeier, Paul T., primary, Yang, Chunyu, primary, Sambel, Larissa A., primary, Färkkilä, Anniina, primary, Reznichenko, Elizaveta, primary, Reavis, Hunter D., primary, Dunn, Connor E., primary, Zou, Lee, primary, Do, Khanh T., primary, Konstantinopoulos, Panagiotis A., primary, Matulonis, Ursula A., primary, Liu, Joyce F., primary, D'Andrea, Alan D., primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

36. Data from ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer

Author

Rafiei, Shahrzad, primary, Fitzpatrick, Kenyon, primary, Liu, David, primary, Cai, Mu-Yan, primary, Elmarakeby, Haitham A., primary, Park, Jihye, primary, Ricker, Cora, primary, Kochupurakkal, Bose S., primary, Choudhury, Atish D., primary, Hahn, William C., primary, Balk, Steven P., primary, Hwang, Justin H., primary, Van Allen, Eliezer M., primary, and Mouw, Kent W., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure Legends from The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition

Author

Parmar, Kalindi, primary, Kochupurakkal, Bose S., primary, Lazaro, Jean-Bernard, primary, Wang, Zhigang C., primary, Palakurthi, Sangeetha, primary, Kirschmeier, Paul T., primary, Yang, Chunyu, primary, Sambel, Larissa A., primary, Färkkilä, Anniina, primary, Reznichenko, Elizaveta, primary, Reavis, Hunter D., primary, Dunn, Connor E., primary, Zou, Lee, primary, Do, Khanh T., primary, Konstantinopoulos, Panagiotis A., primary, Matulonis, Ursula A., primary, Liu, Joyce F., primary, D'Andrea, Alan D., primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

38. Figures S1-S3; Suppl Methods from ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer

Author

Rafiei, Shahrzad, primary, Fitzpatrick, Kenyon, primary, Liu, David, primary, Cai, Mu-Yan, primary, Elmarakeby, Haitham A., primary, Park, Jihye, primary, Ricker, Cora, primary, Kochupurakkal, Bose S., primary, Choudhury, Atish D., primary, Hahn, William C., primary, Balk, Steven P., primary, Hwang, Justin H., primary, Van Allen, Eliezer M., primary, and Mouw, Kent W., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Table 1 from ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer

Author

Rafiei, Shahrzad, primary, Fitzpatrick, Kenyon, primary, Liu, David, primary, Cai, Mu-Yan, primary, Elmarakeby, Haitham A., primary, Park, Jihye, primary, Ricker, Cora, primary, Kochupurakkal, Bose S., primary, Choudhury, Atish D., primary, Hahn, William C., primary, Balk, Steven P., primary, Hwang, Justin H., primary, Van Allen, Eliezer M., primary, and Mouw, Kent W., primary

Published
2023
Full Text
View/download PDF

40. A phase Ia/Ib study of talazoparib in combination with tazemetostat in metastatic castration-resistant prostate cancer (mCRPC).

Author

Choudhury, Atish Dipankar, primary, Xie, Wanling, additional, Tewari, Alok, additional, Miyamoto, David Tomoaki, additional, Kochupurakkal, Bose, additional, Ellis, Leigh, additional, Bandel, Matthew, additional, Leisner, Claire, additional, Shapiro, Geoffrey, additional, D'Andrea, Alan D., additional, Van Allen, Eliezer Mendel, additional, Freedman, Matthew, additional, Brown, Myles, additional, Taplin, Mary-Ellen, additional, and Beltran, Himisha, additional

Published
2022
Full Text
View/download PDF

41. Correlative results from NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.

Author

Bose, Sminu, primary, Ingham, Matthew, additional, Chen, Li, additional, Kochupurakkal, Bose, additional, Marino-Enriquez, Adrian, additional, Allred, Jacob B., additional, George, Suzanne, additional, Attia, Steven, additional, Burgess, Melissa Amber, additional, Seetharam, Mahesh, additional, Boikos, Sosipatros Alexandros, additional, Bui, Nam, additional, Chen, James Lin, additional, Close, Julia Lee, additional, Cote, Gregory Michael, additional, Ivy, S. Percy, additional, Das, Biswajit, additional, Shapiro, Geoffrey, additional, and Schwartz, Gary K., additional

Published
2022
Full Text
View/download PDF

43. Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors

Author

Do, Khanh T., primary, Kochupurakkal, Bose, additional, Kelland, Sarah, additional, de Jonge, Adrienne, additional, Hedglin, Jennifer, additional, Powers, Allison, additional, Quinn, Nicholas, additional, Gannon, Courtney, additional, Vuong, Loan, additional, Parmar, Kalindi, additional, Lazaro, Jean-Bernard, additional, D'Andrea, Alan D., additional, and Shapiro, Geoffrey I., additional

Published
2021
Full Text
View/download PDF

44. NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.

Author

Ingham, Matthew, primary, Allred, Jacob B., additional, Gano, Katherine, additional, George, Suzanne, additional, Attia, Steven, additional, Burgess, Melissa Amber, additional, Seetharam, Mahesh, additional, Boikos, Sosipatros Alexandros, additional, Bui, Nam, additional, Chen, James Lin, additional, Close, Julia Lee, additional, Cote, Gregory Michael, additional, Thaker, Premal H., additional, Ivy, S. Percy, additional, Das, Biswajit, additional, Shapiro, Geoffrey, additional, Kochupurakkal, Bose, additional, Trepel, Jane B., additional, Pommier, Yves, additional, and Schwartz, Gary K., additional

Published
2021
Full Text
View/download PDF

45. A phase 2 study of berzosertib (M6620) in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer.

Author

Choudhury, Atish Dipankar, primary, Xie, Wanling, additional, Folefac, Edmund, additional, Lee, Daniel, additional, Parikh, Mamta, additional, Einstein, David Johnson, additional, Kessler, Elizabeth R, additional, Mayer, Tina M., additional, McKay, Rana R., additional, Pace, Amanda Fredericks, additional, Kochupurakkal, Bose, additional, Mouw, Kent William, additional, Van Allen, Eliezer Mendel, additional, Kunos, Charles, additional, D'Andrea, Alan D., additional, Taplin, Mary-Ellen, additional, and Shapiro, Geoffrey, additional

Published
2021
Full Text
View/download PDF

46. Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer

Author

Keenan, Tanya E., primary, Li, Tianyu, additional, Vallius, Tuulia, additional, Guerriero, Jennifer L., additional, Tayob, Nabihah, additional, Kochupurakkal, Bose, additional, Davis, Janae, additional, Pastorello, Ricardo, additional, Tahara, Rie K., additional, Anderson, Leilani, additional, Conway, Jake, additional, He, Meng X., additional, Shannon, Erin, additional, Godin, Robert E., additional, Sorger, Peter K., additional, D'Andrea, Alan, additional, Overmoyer, Beth, additional, Winer, Eric P., additional, Mittendorf, Elizabeth A., additional, Van Allen, Eliezer M., additional, Shapiro, Geoffrey I., additional, and Tolaney, Sara M., additional

Published
2021
Full Text
View/download PDF

49. ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer

Author

Rafiei, Shahrzad, primary, Fitzpatrick, Kenyon, additional, Liu, David, additional, Cai, Mu-Yan, additional, Elmarakeby, Haitham A., additional, Park, Jihye, additional, Ricker, Cora, additional, Kochupurakkal, Bose S., additional, Choudhury, Atish D., additional, Hahn, William C., additional, Balk, Steven P., additional, Hwang, Justin H., additional, Van Allen, Eliezer M., additional, and Mouw, Kent W., additional

Published
2020
Full Text
View/download PDF

50. Polymerase Theta Inhibition Kills Homologous Recombination Deficient Tumors

Author

Zhou, Jia, primary, Gelot, Camille, additional, Pantelidou, Constantia, additional, Li, Adam, additional, Yücel, Hatice, additional, Davis, Rachel E., additional, Farkkila, Anniina, additional, Kochupurakkal, Bose, additional, Syed, Aleem, additional, Shapiro, Geoffrey I., additional, Tainer, John A., additional, Blagg, Brian S. J., additional, Ceccaldi, Raphael, additional, and D’Andrea, Alan D., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results